Notice NOT-EB-19-014 from the NIH Guide for Grants and Contracts

Notice NOT-AI-19-060 from the NIH Guide for Grants and Contracts

Notice NOT-ES-19-015 from the NIH Guide for Grants and Contracts

Notice NOT-RM-19-009 from the NIH Guide for Grants and Contracts

Competitive: Illumina: ?Responsibilities:Work as part of Agile scrum teams to design, implement, and test our bioinformatics softwareDevelop high quality software based on b Asia

Funding Opportunity PAR-19-309 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to provide support for the development of innovative interventions that improve cancer-related health behaviors across diverse racial/ethnic populations. Specifically, this FOA is intended to stimulate research aimed at 1) testing new theories and conceptual frameworks; 2) developing and evaluating novel strategies to improve cancer-related health behaviors; 3) investigating multi-level and multi-behavioral approaches; and 4) utilizing innovative research designs, methodologies, and technologies. The cancer-related health behaviors to be targeted are diet, obesity, physical activity and sedentary behavior, smoking, sleep and circadian dysfunction, alcohol use, and/or adherence to cancer-related medical regimens. Research can involve any aspect of the cancer continuum and any phase of the translational spectrum.

Funding Opportunity RFA-CA-19-031 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) is a part of the National Cancer Institute (NCI) initiative the Cancer Prevention Clinical Trials Network (CP-CTNet). The CP-CTNet goals are as follows: - Design and conduct of early phase clinical trials to assess the safety, tolerability, and cancer preventive potential of agents and interventions of varying classes, many of which target molecules or processes known to be important during carcinogenesis. These trials include phase 0 (micro-dosing), phase I (dose-finding), and phase II (preliminary efficacy) clinical trials; - Characterization of the effects of these agents and interventions on their molecular targets, as well as on other biological events associated with cancer development (such as cell proliferation, apoptosis, growth factor expression, oncogene expression, immune response) and correlation of these effects with clinical endpoints. - Development of further scientific insights into the mechanisms of cancer prevention by the agents examined, including the development of novel potential markers as determinants of response. CP-CTNet consists of two types of components: - Several CP-CTNet Sites (supported under this FOA and its predecessor RFA-CA-18-029); and - One CP-CTNet Data Management, Auditing, and Coordinating Center (covered by previously issued RFA-CA-18-030). The CP-CTNet Sites will provide scientific leadership in development and conduct of early phase cancer prevention clinical trials as well as in the management and analysis of the data.

Funding Opportunity RFA-AG-20-009 from the NIH Guide for Grants and Contracts. The purpose of the Transition to Aging Research Award for Predoctoral Students is to increase, retain, and diversify the pool of trainees in aging and geriatric research.

Funding Opportunity RFA-CA-19-055 from the NIH Guide for Grants and Contracts. Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) will support the development of technology, tools that will facilitate, accelerate, and/or enhance research using advanced human-derived next generation cancer models, such as organoids, conditionally reprogrammed cells, and others. The studies proposed under this FOA must focus entirely on the next generation cancer models developed under the auspices of an international consortium with NCI participation, Human Cancer Models Initiative. "Technology tools" to be developed under this FOA may include new and/or optimized laboratory methods, reagents/reference materials, agents for NGCMs perturbation or screening read-outs, and/or software/bioinformatics tools for data processing and/or facilitated/enhanced interpretations. (The development of new hardware/equipment will not be supported). The proposed technology tools are expected to a) facilitate the utilization of the cancer models, e.g., in terms of increasing robustness, rigor, and/or reproducibility, b) enable advanced interpretations of experiments in which these model are used, c) design and test CRISPR reagents for all cancer and NGCM types, and d) develop robust approaches to method standardization, quality assurance/control, etc., that could serve as routine workflows/best practices for use in wide range of laboratories. The collective outcomes of projects under this FOA should facilitate the adoption of NGCMs by the research community and expedite sharing and validating of NGCMs-derived results. The new tools and broader use of NCGMs are expected to contribute to the progress in such areas as the identification of novel therapeutic targets, mechanisms of resistance, development of diagnostic and/or predictive biomarkers, and other aspects relevant to precision oncology. This FOA is associated with the Beau Biden Cancer Moonshot SM Initiative that is intended to accelerate cancer research. Specifically, this F

Funding Opportunity PAR-19-307 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support innovative studies to identify and understand the immunological responses that mediate protection from Mycobacterium tuberculosis (Mtb) infection or progression to active tuberculosis (TB) disease. Such responses may be operative in mycobacterial infection, or following vaccination with Bacillus Calmette-Gurin (BCG) or investigational vaccines. Studies may focus on any stage of mycobacterial infection and may include HIV-infected and/or uninfected individuals. Research supported under this FOA should go beyond descriptive information currently known about Mtb infection, immune responses to TB vaccines, or immune modulation by non-tuberculous mycobacterial (NTM) infection, or by HIV/AIDS. Applications are sought that include characterization of the timing, anatomical location, and contribution to disease outcome, of mucosal and/or systemic immune responses to mycobacterial infection and/or vaccination. This research is expected to advance understanding of immune mechanisms in Mtb infection/vaccination and contribute to the advancement of new TB vaccines, including in populations also infected with HIV.

Notice NOT-NS-19-073 from the NIH Guide for Grants and Contracts

Notice NOT-NS-19-074 from the NIH Guide for Grants and Contracts

Notice NOT-NS-19-072 from the NIH Guide for Grants and Contracts

Notice NOT-DK-19-017 from the NIH Guide for Grants and Contracts

Competitive: Illumina: Tasks and Responsibilities:Coordinate new installations, including facility inspections, and assay validationProvide comprehensive technical training Asia

Competitive: Illumina: Position Summary:As a Field Applications Scientist you are involved in providing customer support regarding Illumina's equipment and tools. You are re Asia

Competitive: Illumina: Position Summary:As Field Applications Scientist, you will provide applications support (installation, system validation, customer training) to custom South Wales, Wales

Competitive: Illumina: Responsibilities:Work as part of Agile scrum teams to test our bioinformatics softwareDevelop and execute automated API/UI/Unit tests to enable contin Asia

Competitive: Illumina: We are seeking an exceptional engineer to join our growing Life Cycle Management (LCM) team to contribute to the development and maintenance of Illumi San Diego, California (US)

Competitive: Illumina: This role is to provide leadership and support for software verification of Illumina’s data analysis software. As a Staff Software Test Engineer, you San Diego, California (US)